Presynaptic, Activity-dependent Modulation of Cannabinoid Type 1 Receptor-mediated Inhibition of GABA Release
Overview
Affiliations
Endocannabinoid signaling couples activity-dependent rises in postsynaptic Ca2+ levels to decreased presynaptic GABA release. Here, we present evidence from paired recording experiments that cannabinoid-mediated inhibition of GABA release depends on the firing rates of the presynaptic interneurons. Low-frequency action potentials in post hoc identified cholecystokinin-positive CA1 basket cells elicited IPSCs in the postsynaptic pyramidal cells that, as expected, were fully abolished by the exogenous application of the cannabinoid receptor agonist WIN55,212-2 [R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol[1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone monomethanesulfonate] at 5 microM. However, the presynaptic basket cells recovered from the cannabinoid agonist-induced inhibition of GABA release when the presynaptic firing rate was increased to > or =20 Hz. Pharmacological experiments showed that the recovered transmission was exclusively dependent on presynaptic N-type Ca2+ channels. Furthermore, the increased presynaptic firing could also overcome even complete depolarization-induced suppression of inhibition, indicating that the magnitude of DSI markedly depends on the activity levels of basket cells. These results reveal a new locus of activity-dependent modulation for endocannabinoid signaling and suggest that endocannabinoid-mediated inhibition of GABA release may differ in distinct behavioral states.
Presynaptic nanoscale components of retrograde synaptic signaling.
Barti B, Dudok B, Kenesei K, Zoldi M, Miczan V, Balla G Sci Adv. 2024; 10(22):eado0077.
PMID: 38809980 PMC: 11135421. DOI: 10.1126/sciadv.ado0077.
Retrograde endocannabinoid signaling at inhibitory synapses in vivo.
Dudok B, Fan L, Farrell J, Malhotra S, Homidan J, Kim D Science. 2024; 383(6686):967-970.
PMID: 38422134 PMC: 10921710. DOI: 10.1126/science.adk3863.
Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy.
Jahncke J, Miller D, Krush M, Schnell E, Wright K Elife. 2024; 12.
PMID: 38179984 PMC: 10942650. DOI: 10.7554/eLife.87965.
Wiesman A, da Silva Castanheira J, Fon E, Baillet S Ann Neurol. 2023; 95(4):802-816.
PMID: 38146745 PMC: 11023768. DOI: 10.1002/ana.26871.
Zirotti Rosenberg A, Mendez-Ruette M, Gorziglia M, Alzerreca B, Cabello J, Kaufmann S Front Mol Neurosci. 2022; 15:868583.
PMID: 36147210 PMC: 9488559. DOI: 10.3389/fnmol.2022.868583.